2A7

2A7 is a novel monoclonal antibody developed by researchers at The University of Texas MD Anderson Cancer Center that specifically targets the N-terminal extracellular domain of low-density lipoprotein receptor-related protein 1 (LRP1). LRP1 is a multifunctional receptor involved in lipid metabolism and cell signaling, which is significantly upregulated on the surface of activated T cells and chimeric antigen receptor (CAR) T cells. 2A7 was selected for its high binding affinity (KD = 3.67x10-10 M) and specificity compared to existing commercial antibodies like 8G1. It serves as a biomarker for T cell activation and identifies a subset of CAR-T cells that maintain an activated state, potentially aiding in the characterization and optimization of T-cell-based immunotherapies.

Other names

2A7 monoclonal antibodyanti-LRP1 antibody 2A7anti-LRP-1 antibody 2A7anti-LRP 1 antibody 2A7